Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D005469:Fluorometholone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D013738:Testolactone / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013738:Testolactone; D008525:Medroxyprogesterone; D005469:Fluorometholone